Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:GNCA
Date2/2014
Raised$66M
Post IPO Valuation

General Information

Websitegenocea.com
CategoryBioTech
Phone617.876.8191
Emailwebsite.inquiry@g...
Employees
Founded2006

Offices

Cambridge, USA
161 First St.
Suite 2C
Cambridge, MA, 02142
USA

People

CEO
VP Finance and Admininstration
Vice President, Research
VP, Development
Vice President, Business Development
Board of Directors
Board of Directors
Board of Directors
Show All People

Funding

Tags

Genocea Biosciences

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The company expects to begin clinical trials for its lead program, a therapeutic vaccine for HSV-2, in early 2011.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Genocea Biosciences Closes $35M Series B Financing Round (finsmes.com) [edit]
  2. Genocea raises $30M to advance herpes vaccine (masshightech.com) [edit]
  3. SEC (sec.gov) [edit]
  4. Genocea's $35M VC round pushing herpes vaccine toward clinic (masshightech.com) [edit]
    Clark named CEO at Genocea Biosciences (masshightech.com) [edit]
Edit This Page
Last Edited 2/5/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy